// App-Quantinova.ai

2582 : Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

Researchers

Presenter

  • Maen A. Hussein

Principal Investigators

  • Ivor John Percent

  • Johanna C. Bendell

  • Edward Arrowsmith

  • Hendrik-Tobias Arkenau

  • Quincy S. Chu

  • Aaron Richard Hansen

  • Damijan Erzen

  • Sheng Qiu

  • Anthony Lucarelli

  • Susanna Varkey Ulahannan

Medical Centers

  • Florida Cancer Specialists, Lady Lake, FL and Sarah Cannon Research Institute, Nashville, TN

  • Florida Cancer Specialists, Port Charlotte, FL

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • CHI Memorial Hospital, Chattanooga, TN

  • Sarah Cannon Research Institute and University College London Cancer Institute, London, United Kingdom

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Canada.

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

  • Sarah Cannon Research Institute, Nashville, TN and University of Oklahoma Health Sciences Center-Stephenson Cancer Center, Oklahoma City, OK

Locations

  • United States

  • United Kingdom

  • Canada

  • Germany

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Solid malignancies

  • Endometrial Cancer

  • Colorectal Cancer

  • Melanoma

  • Non Small Cell Lung cancer

Biomarkers

  • Vascular endothelial growth factor A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT03697304

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved